tirzepatide 2.5 mg/0.5ml solution pen-injector EU drug regulator to review Lilly's Mounjaro in multi-dose pen Mounjaro 2.5mg/0.5ml Injection In Pre-Filled

That claim isnt backed by science

While most compounding pharmacies are reputable and follow rigorous safety standards, some may not, which introduces the chance of risk

Minimal Downtime : Most patients can return to their normal activities quickly

--- This year brought 26 biosimilars that were approved by the FDA A significant portion of them (16) were denosumab biosimilars: 8 biosimilars referencing Prolia (denosumab for osteoporosis) Additional 8 biosimilars referencing Xgeva (denosumab for cancer-related bone disease) The downstream effects compound: Biosimilars typically reduce costs by 15-35% compared to reference products (this can decrease more as additional biosimilar options become available) Price competition benefits the entire therapeutic category Patients who couldn't afford brand therapy now have accessible options Health systems gain formulary flexibility without compromising clinical outcomes --- The 26 biosimilar approvals in 2025 represent thousands of patients gaining affordable access to proven therapies that may have previously been out of reach